News

News

Press Releases

Oct 04, 2019
Tricida to Host Investor Day on October 15, 2019
  Management to unveil veverimer (TRC101) U.S. commercialization strategy following recent NDA submission     Leading clinicians and researchers to discuss implications of metabolic acidosis     Live and archived webcast available     SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct.
Aug 08, 2019
Tricida Announces Second Quarter 2019 Financial Results
Narrows Timing of Planned NDA Submission to the Third Quarter of 2019 Back-to-Back Publications in ‘The Lancet’ Highlight Positive Clinical Trial Results of Veverimer Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 8, 2019-- Tricida, Inc.
May 08, 2019
Tricida Announces First Quarter 2019 Financial Results
Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 8, 2019-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed